Kobayashi, Kazuo http://orcid.org/0000-0002-9615-0489
Sugiyama, Erika
Shinozaki, Eiji
Wakatsuki, Takeru
Tajima, Masataka
Kidokoro, Hiyori
Aoyama, Takeshi http://orcid.org/0000-0002-0767-2606
Nakano, Yasuhiro
Kawakami, Kazuyoshi http://orcid.org/0000-0003-2023-1300
Hashimoto, Koki
Suenaga, Mitsukuni
Ichimura, Takashi
Ogura, Mariko
Chin, Keisho
Nakayama, Izuma
Ooki, Akira
Takahari, Daisuke
Suzuki, Wataru
Yokokawa, Takashi http://orcid.org/0000-0001-9988-128X
Minowa, Yuichi
Hiraoka, Tomoko
Suzuki, Kenichi
Sato, Hitoshi
Hama, Toshihiro
Yamaguchi, Kensei
Funding for this research was provided by:
Japan Research Foundation for Clinical Pharmacology
Article History
Received: 23 October 2020
Accepted: 20 January 2021
First Online: 26 February 2021
Compliance with ethical standards
:
: K. Yamaguchi has received speaking honorariums from Taiho Pharmaceutical, Chugai Pharmaceutical, Merck Serono, Takeda Pharmaceutical, Yakult, Bayer, Ono Pharmaceutical, Eli Lilly, Sanofi and Bristol-Myers Squibb, and has received research grants from MSD, Ono Pharmaceutical, Sumitomo Dainippon Pharma, Taiho Pharmaceutical, Daiichi Sankyo, Eli Lilly, Gilead Sciences, and Yakult. Also, he has served in a consulting or advisory role for Bristol-Myers Squibb. The other authors declare that they have no conflicts of interest.
: This study was conducted in accordance with the World Medical Association Declaration of Helsinki and independently reviewed and approved by the Clinical Research Ethics Review Committee of the hospital (approval no. 2017-1205). All patients provided written informed consent for the use of their blood samples and medical information for research purposes. This study was registered at the University Hospital Medical Information Network Clinical Trials Registry (UMIN no. 000032725).